Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The term "Inflammatory mediator release from monocyte-macrophages induced by endotoxin" refers to a complex biological process rather than a discrete molecular target. When exposed to endotoxins—primarily lipopolysaccharide (LPS) from Gram-negative bacteria—monocytes and macrophages become activated through pattern recognition receptors such as Toll-like receptor 4 (TLR4) with co-receptors like CD14. This activation triggers intracellular signaling cascades that result in the rapid production and secretion of pro-inflammatory mediators including tumor necrosis factor-alpha (TNF‑α), interleukin‑1 beta (IL‑1β), interleukin‑6, prostaglandins, chemokines like MCP‑1/CCL2 and IL‑8/CXCL8, among others[1][5][7]. These mediators orchestrate both local and systemic immune responses. This process is central to host defense against infection but can also lead to pathological inflammation seen in conditions such as sepsis or chronic inflammatory diseases if dysregulated. The phenomenon known as "endotoxin tolerance," where repeated exposure leads to hyporesponsiveness of monocytes/macrophages with altered cytokine profiles, further complicates therapeutic strategies[2][3][6]. Because this entry describes an entire cellular response rather than a single protein or gene product typically considered a druggable target ("receptor," "enzyme," etc.), it should not be classified as an individual therapeutic target. Instead, drug development efforts focus on modulating key molecules within this cascade—such as blocking TLR4 activation or neutralizing specific cytokines—to control excessive inflammation without compromising essential immune functions. In summary: This is not a canonical molecular target but rather describes an important immunological mechanism involving multiple proteins and pathways central to innate immunity and inflammation[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Inflammatory mediator release from monocyte-macrophages induced by endotoxin.